Journal of Thrombosis and Haemostasis

Volume Contents
pp. i-ii(2)

Malignancy, thrombosis and Trousseau: the case for an eponym
pp. 2463-2465(3)
Author: Khorana A.A.

A definite role for treatment with activated protein C in sepsis? Yes
pp. 2466-2468(3)
Authors: Wiel E.; Vallet B.

A definite role for treatment with activated protein C in sepsis? Standard use is premature
pp. 2469-2471(3)
Authors: Girbes A.R.J.; Polderman K.H.

Good things come in small packages for hemophilia
pp. 2472-2473(2)
Author: Kaufman R.J.

Prevention of venous thromboembolism after major orthopedic surgery: ‘new’ clinical trials for new antithrombotic agents
pp. 2474-2476(3)
Author: Mismetti P.

Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII
pp. 2477-2489(13)
Authors: Wilcox D.A.; Shi Q.; Nurden P.; Haberichter S.L.; Rosenberg J.B.; Johnson B.D.; Nurden A.T.; Ii G.C.W.; Montgomery R.R.

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study
pp. 2490-2496(7)
Authors: Eriksson B.I.; Agnelli G.; Cohen A.T.; Dahl O.E.; Lassen M.R.; Mouret P.; Rosencher N.; Kälebo P.; Panfilov S.; Eskilson C.; Andersson M.

Heterologous cell–cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1)
pp. 2497-2509(13)
Authors: Marcus A.J.; Broekman M.J.; Drosopoulos J.H.F.; Islam N.; Pinsky D.J.; Sesti C.; Levi R.

Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways
pp. 2510-2515(6)
Authors: So A.K.; Varisco P-A.; Kemkes-Matthes B.; Herkenne-Morard C.; Chobaz-Péclat V.; Gerster J-C.; Busso N.

Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome
pp. 2516-2522(7)
Authors: Van Ommen C.H.; Heijboer H.; Van Den Dool E.J.; Hutten B.A.; Peters M.

Individualized duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model
pp. 2523-2530(8)
Authors: Vink R.; Kraaijenhagen R.A.; Levi M.; Büller H.R.

Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance
pp. 2531-2535(5)
Authors: Antovic A.; Blombäck M.; Bremme K.; Van Rooijen M.; He S.

Elevated plasma levels of factor VIII in women with early recurrent miscarriage
pp. 2536-2539(4)
Authors: Marietta M.; Facchinetti F.; Sgarbi L.; Simoni L.; Bertesi M.; Torelli G.; Volpe A.

Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients
pp. 2540-2547(8)
Authors: Ciccarone E.; Di Castelnuovo A.; Assanelli D.; Archetti S.; Ruggeri G.; Salcuni N.; Donati M.B.; Capani F.; Iacoviello L.

Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay
pp. 2548-2553(6)
Authors: Ling M.; Duncan E.M.; Rodgers S.E.; Street A.M.; Lloyd J.V.

Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression
pp. 2554-2560(7)
Authors: Ungerstedt J.S.; Heimersson K.; Söderström T.; Hansson M.

Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner
pp. 2561-2568(8)
Authors: Biró É.; Sturk-Maquelin K.N.; Vogel G.M.T.; Meuleman D.G.; Smit M.J.; Hack C.E.; Sturk A.; Nieuwland R.

Superantigens from Staphylococcus aureus induce procoagulant activity and monocyte tissue factor expression in whole blood and mononuclear cells via IL-1
pp. 2569-2576(8)
Authors: Mattsson E.; Herwald H.; Egesten A.

An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF–VIIa–Xa): a protein–protein docking and molecular dynamics refinement study
pp. 2577-2588(12)
Authors: Venkateswarlu D.; Duke R.E.; Perera L.; Darden T.A.; Pedersen L.G.

Highly accumulated platelet vascular endothelial growth factor in coagulant thrombotic region
pp. 2589-2593(5)
Authors: Arisato T.; Hashiguchi T.; Sarker K.P.; Arimura K.; Asano M.; Matsuo K.; Osame M.; Maruyama I.

A monoclonal antibody to the fibrinogen -chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles
pp. 2594-2602(9)
Authors: Scheiner T.; Jirouková M.; Nagaswami C.; Coller B.S.; Weisel J.W.

Problems relating to the laboratory diagnosis of factor XIII deficiency: a UK NEQAS study
pp. 2603-2608(6)
Authors: Jennings I.; Kitchen S.; Woods T.A.L.; Preston F.E.

DNA variation in a 13-Mb region including the F9 gene: inferring the genealogical history and causal role of a hemophilia B mutation (IVS 5+13 AG)
pp. 2609-2614(6)
Authors: Anagnostopoulos T.; Morris A.P.; Ayres K.L.; Giannelli F.; Green P.M.

Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1
pp. 2615-2620(6)
Authors: Urano T.; Castellino F.J.; Ihara H.; Suzuki Y.; Ohta M.; Suzuki K.; Mogami H.

Safety of plasmin in the setting of concomitant aspirin and heparin administration in an animal model of bleeding
pp. 2621-2625(5)
Authors: Sadeghi S.; Marder V.J.; Stewart D.; Kong M.; Humphries J.; Baumbach G.A.; Jesmok G.

Potentiation of platelet activation through the stimulation of P2X₁ receptors
pp. 2626-2635(10)
Authors: Erhardt J.A.; Pillarisetti K.; Toomey J.R.

A peptide isolated from B-crystallin is a novel and potent inhibitor of platelet aggregation via dual prevention of PAR-1 and GPIb/V/IX
pp. 2636-2642(7)
Authors: Matsuno H.; Ishisaki A.; Nakajima K.; Kato K.; Kozawa O.

A palmitylated peptide derived from the glycoprotein Ib cytoplasmic tail inhibits platelet activation
pp. 2643-2652(10)
Authors: Martin K.; Meade G.; Moran N.; Shields D.C.; Kenny D.

Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments
pp. 2653-2662(10)
Authors: Lecut C.; Feeney L.A.; Kingsbury G.; Hopkins J.; Lanza F.; Gachet C.; Villeval J-L.; Jandrot-Perrus M.

The effect of the anorectic agent, d-fenfluramine, and its primary metabolite, d-norfenfluramine, on intact human platelet serotonin uptake and efflux
pp. 2663-2668(6)
Authors: Johnson G.J.; Leis L.A.; Dunlop P.C.; Weir E.K.

Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice
pp. 2669-2674(6)
Authors: Wilson K.M.; Lynch C.M.; Faraci F.M.; Lentz S.R.

Unusual expression of the F9 gene in peripheral lymphocytes hinders investigation of F9 mRNA in hemophilia B patients
pp. 2675-2676(2)
Authors: Green P.M.; Rowley G.; Giannelli F.

High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly
pp. 2677-2678(2)
Authors: Van Hylckama Vlieg A.; Rosendaal F.R.

Local endothelial function and leg symptoms in patients after deep vein thrombosis
pp. 2679-2681(3)
Authors: Kolbach D.N.; Van Oerle R.; Hamulyák K.; Neumann H.A.M.; Prins M.H.

A new rapid bedside assay ford-dimer measurement (Simplifyd-dimer) in the diagnostic work-up for deep vein thrombosis
pp. 2681-2683(3)
Authors: Cini M.; Legnani C.; Cavallaroni K.; Bettini F.; Palareti G.

Rapid detection of the prothrombin C20209T variant by differential sensitivity to restriction endonuclease digestion
pp. 2683-2685(3)
Authors: Ozelo M.C.; Annichino-Bizzacchi J.M.; Pollak E.S.; Russell J.E.

Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome
pp. 2685-2687(3)
Authors: Morel O.; Jesel L.; Chauvin M.; Freyssinet J.M.; Toti F.

The C-1T mutation in the annexin A5 Kozak sequence slightly increases the risk of myocardial infarction in men
pp. 2688-2689(2)
Authors: Kenis H.; Doggen C.J.M.; Vos H.L.; Reutelingsperger C.P.M.; van Heerde W.L.

Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant
pp. 2689-2691(3)
Authors: Thom J.; Ivey L.; Eikelboom J.

The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)--stimulated cells
pp. 2691-2692(2)
Authors: Arkel Y.S.; Ku D-H.W.; Thurston A.L.

Prevalence of factor XIII deficiency in patients presenting with a bleeding disorder in Pakistan
pp. 2693-2694(2)
Authors: Anwar M.; Iqbal M.; Ayyub M.; Ali W.

Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days
pp. 2694-2695(2)
Authors: Gouin-Thibault I.; Pautas E.; Depasse F.; Andreux J.P.; Siguret V.

Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism
pp. 2696-2697(2)
Authors: Imberti D.; Verso M.; Silvestrini E.; Taliani M.R.; Agnelli G.

Selection bias largely explains the differential distribution of factor V Leiden in different patient populations between the centers – a rebuttal
pp. 2697-2698(2)
Authors: Mohanty D.; Ghosh K.; Shetty S.

Choice of replacement therapy for hemophilia—a rebuttal
pp. 2698-2699(2)
Author: Giangrande P.L.F.

Choice of replacement therapy for hemophilia—reply to a rebuttal
pp. 2699-2700(2)
Author: Shanbrom E.

Effect of prolonged sitting on thrombin generation: not evidenced yet: rebuttal
pp. 2700-2700(1)
Authors: Schreijer A.J.M.; Cannegieter S.C.; Rosendaal F.R.

Announcements
pp. 2701-2701(1)

PRIZE PICTURES
pp. 2702-2703(2)

Author Index
pp. 2704-2715(12)

Subject Index
pp. 2716-2721(6)

Corrigendum
pp. 2722-2722(1)

Erratum
pp. 2722-2722(1)